CurrentBlue Cross Blue Shield - MassachusettsPolicy 287

Cardiac Hemodynamic Monitoring for the Management of Heart Failure in the Outpatient Setting

Defines Blue Cross Blue Shield Massachusetts medical policy #287 on cardiac hemodynamic monitoring technologies (implantable pulmonary artery pressure sensors, thoracic bioimpedance, inert gas rebreathing, arterial pressure during Valsalva) for management of heart failure in ambulatory/outpatient and inpatient settings, including investigational status, coding, authorization requirements, and evidence summary.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyCardiac Hemodynamic Monitoring for the Management of Heart Failure in the Outpatient Setting

Policy CodePolicy 287

Change TypeAnnual review; clarification (inpatient placement investigational)

Effective Date

Next Review Date

Key ActionPrecertification/prior authorization is required for all products if the procedure is performed inpatient.

POLICY UPDATE CHANGES

Annual policy review updated with literature review through April 4, 2025; references updated.

Policy clarified to include that placement of implantable cardiac hemodynamic devices in the inpatient setting is considered investigational (12/2021).

4Monitoring modalities discussed

3CPT/HCPCS codes listed as investigational

InsufficientEvidence to determine net health benefit

Coverage Summary

Overview: This policy addresses outpatient cardiac hemodynamic monitoring intended to detect physiologic changes to guide early interventions for heart failure and to reduce decompensation and hospitalizations. Monitored modalities discussed include implantable pulmonary artery (PA) pressure sensors (e.g., CardioMEMS, Cordella), thoracic bioimpedance, inert gas rebreathing, and arterial pressure measurement during the Valsalva maneuver.

Scope summary: The policy defines coverage and investigational determinations for cardiac hemodynamic monitoring technologies in ambulatory/outpatient and inpatient settings, including coding and prior authorization requirements. Evidence reviewed includes randomized controlled trials, nonrandomized studies, meta-analyses, and registry/post-approval data primarily for implantable PA pressure sensors.

Evidence conclusion: The available evidence is insufficient to determine an improvement in net health outcomes for the technologies reviewed. Implantable PA sensors have mixed trial results (for example, CHAMPION showed a reduction in heart-failure hospitalizations while GUIDE-HF and subsequent analyses raised uncertainty), and noninvasive modalities lack RCT evidence demonstrating clinical benefit.

Monitoring modalities discussed: implantable PA pressure sensors, thoracic bioimpedance, inert gas rebreathing, and arterial pressure during the Valsalva maneuver are explicitly reviewed in the policy as monitoring approaches considered in outpatient heart failure management.

Policy metadata

policy_number287

subjectCardiac Hemodynamic Monitoring for Outpatient Heart Failure

statusCURRENT

dates.last_review2025-08

scope_summaryDefines Blue Cross Blue Shield Massachusetts medical policy #287 on cardiac hemodynamic monitoring technologies (implantable pulmonary artery pressure sensors, thoracic bioimpedance, inert gas rebreathing, arterial Valsalva) for management of heart failure in ambulatory/outpatient and inpatient settings, including investigational status, coding, authorization requirements, and evidence summary.

Investigational / Coverage Determinations

Commercial Members - Investigational determinations

Policy statements regarding investigational status and coverage in ambulatory/outpatient and inpatient settings:

Cardiac hemodynamic monitoring using implantable direct pressure monitoring of the pulmonary artery, thoracic bioimpedance, inert gas rebreathing, and arterial pressure during the Valsalva maneuver is considered INVESTIGATIONAL.

Applies to ambulatory care and outpatient setting; statement includes inpatient placement of the device.

Placement of implantable cardiac hemodynamic devices in the inpatient setting is considered investigational.

Policy history clarifies inpatient placement investigational.

Precertification / Prior Authorization requirements

Authorization requirements as stated:

Precertification/prior authorization IS REQUIRED for all products if the procedure is performed inpatient.

Applies to services described in this policy.

For certain products, prior authorization might be required if the procedure is performed outpatient; Commercial Managed Care (HMO and POS) outpatient is not a covered service; Commercial PPO and Indemnity outpatient is not a covered service.

Commercial PPO and Indemnity outpatient: not a covered service; Managed Care outpatient: not a covered service as stated.

Coding — Investigational / Experimental Codes

CPT codes considered investigational for Commercial MembersCPTExperimental

33289	Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring; including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision.
93264	Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional.
93701	Bioimpedance-derived physiologic cardiovascular analysis.

HCPCS codes considered investigational for Commercial MembersHCPCSExperimental

C2624

Implantable wireless pulmonary artery pressure sensor with delivery catheter, including all system components

Actions for Providers

Prior Authorization

Precertification required for inpatient procedures

Precertification/prior authorization is required for all products if the procedure is performed inpatient.

Prior Authorization

Outpatient coverage differs by product and product line

Commercial Managed Care (HMO and POS) outpatient: not a covered service; Commercial PPO and Indemnity outpatient: not a covered service; check product-specific prior authorization requirements where noted.

Documentation Required

Report services with current codes and modifiers

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

Denial Risk

Investigational procedures are non-covered

Claims for procedures/technologies determined investigational (implantable pulmonary artery pressure sensors and listed monitoring modalities) are not considered covered for Commercial Members; denial risk if billed for investigational services.

33289
93264
93701
C2624

Evidence Summary

Background (technologies reviewed): The policy reviews four outpatient hemodynamic monitoring methods: implantable pulmonary artery pressure sensors (including devices such as CardioMEMS and Cordella), thoracic bioimpedance, inert gas rebreathing, and arterial waveform/pressure measurement during the Valsalva maneuver.

Overall evidence assessment: Evidence for implantable PA sensors includes randomized controlled trials (for example, CHAMPION, GUIDE-HF, MONITOR-HF), nonrandomized studies, post-approval registries, and meta-analyses. Results are mixed — some trials report reductions in heart-failure hospitalizations and improvements in quality of life, while others fail to meet primary endpoints or have methodological concerns (including potential bias from additional nurse interventions and the impact of COVID-19). For thoracic bioimpedance, inert gas rebreathing, and arterial Valsalva monitoring, the evidence is limited or lacking (few or no RCTs and mostly uncontrolled studies or single studies).

Policy conclusion: Given the conflicting or limited evidence, the policy states that the evidence is insufficient to determine that these technologies improve net health outcomes and therefore treats these monitoring modalities as investigational in the outpatient context; associated CPT and HCPCS codes for implantable PA sensors and listed modalities are designated investigational for Commercial Members.

Key evidence

CHAMPION trialPivotal RCT (CardioMEMS) reported a 28% decrease in heart-failure hospitalizations vs usual care; FDA reviewed analyses and post-approval studies reported decreased HF hospitalizations but concerns about potential bias from nurse interventions and procedural complications.

GUIDE-HFRandomized trial failed to meet primary composite endpoint overall; pre-COVID-19 subgroup (72% of patients) showed a 19% reduction in the primary endpoint driven by a 28% reduction in HF hospitalizations; COVID-19 effects add imprecision.

MONITOR-HFOpen-label RCT in the Netherlands showed improved KCCQ quality-of-life scores and reduced HF hospitalizations but no mortality benefit at 1 year.

Term	Definition
Investigational	Procedures or technologies not considered established as safe and effective for the specific indication and therefore not covered.
CardioMEMS	An implantable wireless pulmonary artery pressure sensor system with FDA approval for hemodynamic monitoring.

Name	Type	Number	Effective Date
Monitoring by thoracic electrical bioimpedance (TEB)	NCD